Skip to main content
. 2015 Apr 13;125(5):2007–2020. doi: 10.1172/JCI78124

Figure 5. Ash1l deficiency allows engraftment of wild-type HSCs in the absence of myeloablation.

Figure 5

(A) Experimental strategy: B6-CD45.2 Ash1l+/+ or Ash1lGT/GT mice received 2 × 107 B6-CD45.1 or B6-GFP BM cells (2 doses 1 week apart i.v.), without prior irradiation. (B) Analysis of peripheral blood, showing myeloid, B, and T cell output from CD45.1+ donor BM in 7 of 8 Ash1lGT/GT recipients versus 0 of 6 Ash1l+/+ recipients (data from 3 experiments). Lines represent individual recipients. Reconstitution was sustained for ≥12 weeks. (C) Flow cytometric analysis of LT-HSCs 12 to 21 weeks after infusion, showing donor LT-HSC engraftment in 7 of 8 Ash1lGT/GT recipients versus 0 of 6 wild-type recipients (pooled from 3 experiments, with horizontal bars showing the mean; ***P < 0.001, t test).